在路线图中的突破 IL-35介导的免疫疗法用于1型和自身免疫性糖尿病
Ratul Chakraborty1, Ashis K Mukherjee2, Asis Bala1
1Pharmacology and Drug Discovery Research Laboratory, Division of Life Sciences, Institute of Advanced Study in Science and Technology (IASST), Vigyan Path, Guwahati 781035, Assam, India; Academy of Scientific and Innovative Research (AcSIR), AcSIR (an Indian Institute of National Importance), Sector 19, Kamla Nehru Nagar, Ghaziabad, Uttar Pradesh 201002, India.
Cytokine
|July 10, 2024
概括
介素-35 (IL-35) 通过调节免疫细胞,在治疗1型和自身免疫性糖尿病方面表现有前途. 需要进一步的研究来确认其在糖尿病管理中的治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 生物化学 生物化学
背景情况:
- 介素-35 (IL-35) 是一种由IL-12α和IL-27β链组成的细胞因子.
- 糖尿病是一种日益严重的全球健康问题,特别是1型和自身免疫形式.
- 目前的糖尿病治疗方法需要进一步开发,这促使人们对新的治疗点进行研究.
研究的目的:
- 审查目前关于IL-35在糖尿病中的作用的研究.
- 探索IL-35作为治疗1型和自身免疫糖尿病的治疗剂的潜力.
- 突出IL-35在糖尿病相关的免疫反应中的调节功能.
主要方法:
- 关于IL-35和糖尿病的最新科学出版物的文献综述.
- 对研究IL-35对免疫细胞群和细胞因子概况的影响的研究分析.
- 关于IL-35对巨分化,T细胞细胞因子和调控性B细胞 (Bregs) 的影响的综合证据.
主要成果:
- IL-35被认为是1型和自身免疫性糖尿病的关键调节剂.
- 研究表明,IL-35对这些糖尿病形式产生保护作用.
- IL-35影响巨细胞的偏振,T细胞细胞因子和调控性B细胞.
结论:
- IL-35在糖尿病治疗中显示出免疫疗法的巨大潜力.
- 了解IL-35的机制可能会导致针对自身免疫和1型糖尿病的新型治疗策略.
- 进一步的调查和临床试验对于验证IL-35的疗效和安全至关重要.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
Tumor Immunotherapy
509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Pathophysiology of Diabetes
917
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
917
Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313


